Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 1

Conditions

Breast Neoplasms 8Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Intraocular Lymphoma 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1

Interventions

aldesleukin 23Bevacizumab 17Magnetic Resonance Spectroscopy 15Specimen Handling 12Sunitinib 11Sorafenib 11Interferon-alpha 11cabozantinib 9Cyclophosphamide 9Nivolumab 8Immunoglobulin G 7Disulfides 7temsirolimus 6fludarabine phosphate 5Sirolimus 5Introns 5Fluorouracil 5Erlotinib Hydrochloride 5Chemotherapy, Adjuvant 5sargramostim 4cediranib 4bryostatin 1 4Vorinostat 4Neoadjuvant Therapy 4Ipilimumab 4Interleukin-2 4Interferon alpha-2 4Biopsy 4vandetanib 3ixabepilone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoma, Renal Cell × MK 2206 × Clear all
NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT01239342 2019-10-10

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
43 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡